FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Healthcare

After an over decade-long discourse amongst interested stakeholders, on October 3, 2023, FDA unveiled its proposed rule and policy to increase oversight over LDTs.

Related Keywords

,York State Department Of Health ,Clinical Laboratory Evaluation Program ,Veterans Health Administration ,Public Health Surveillance ,Academic Medical Centers Amcs ,Clinical Laboratory Improvement Amendments ,Tests Subject ,Phaseout Policy ,Leukocyte Antigen ,Law Enforcement ,Public Health ,Remain Under Active ,Federal Food ,Cosmetic Act ,Blood Donor Screening ,Phaseout Timeline ,Device User Fee Amendments ,Unique Device Identification ,Device Exemption ,Small Business Determination ,Small Business ,Devices Program ,Safer Technologies Program ,Medical Centers ,New York State Department ,Veterans Health ,Q Submission Program ,Consolidated Appropriations Act ,Sunshine Act ,Mondaq ,Fdas Proposed Rule For Oversight Of Laboratory Developed Tests Part Ii Fda Amp 39s Phaseout Policy X2013 Key Considerations Open Questions ,Compliance ,Food ,Drugs ,Healthcare ,Life Sciences ,Iotechnology Amp Nanotechnology ,